op banner. Branded banner with the words 'THE FIRST APPROVED GENE THERAPY FOR AN INHERITED RETINAL DYSTROPHY' and 'A future of possibilities for your patients with an RPE65 mutation-associated inherited retinal dystrophy'.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]